PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.31%
Revenue growth at 50-75% of MRVL's 4.29%. Martin Whitman would worry about competitiveness or product relevance.
3.64%
Gross profit growth similar to MRVL's 3.82%. Walter Schloss would assume both firms track common industry trends.
12.92%
EBIT growth above 1.5x MRVL's 8.09%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
10.33%
Operating income growth at 50-75% of MRVL's 15.99%. Martin Whitman would doubt the firm’s ability to compete efficiently.
34.92%
Positive net income growth while MRVL is negative. John Neff might see a big relative performance advantage.
33.33%
Positive EPS growth while MRVL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
33.33%
Positive diluted EPS growth while MRVL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-29.56%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-27.87%
Reduced diluted shares while MRVL is at 1.17%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
41.96%
Maintaining or increasing dividends while MRVL cut them. John Neff might see a strong edge in shareholder returns.
-48.82%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-112.03%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
3.06%
10Y revenue/share CAGR under 50% of MRVL's 56.20%. Michael Burry would suspect a lasting competitive disadvantage.
-24.01%
Negative 5Y CAGR while MRVL stands at 109.65%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-27.73%
Negative 3Y CAGR while MRVL stands at 25.49%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
-52.04%
Negative 5Y OCF/share CAGR while MRVL is at 45.44%. Joel Greenblatt would question the firm’s operational model or cost structure.
385.77%
3Y OCF/share CAGR above 1.5x MRVL's 63.72%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
143.28%
Below 50% of MRVL's 653.69%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
73.69%
Below 50% of MRVL's 220.76%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
48.33%
Below 50% of MRVL's 202.86%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
145.52%
5Y equity/share CAGR above 1.5x MRVL's 19.67%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
49.68%
Positive short-term equity growth while MRVL is negative. John Neff sees a strong advantage in near-term net worth buildup.
83.48%
10Y dividend/share CAGR above 1.5x MRVL's 0.04%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
77.18%
Stable or rising mid-term dividends while MRVL is cutting. John Neff sees an edge in consistent payouts vs. the competitor.
-2.22%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
7.14%
AR growth well above MRVL's 11.24%. Michael Burry fears inflated revenue or higher default risk in the near future.
3.72%
Inventory growth well above MRVL's 4.05%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-1.20%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
45.27%
Positive BV/share change while MRVL is negative. John Neff sees a clear edge over a competitor losing equity.
-3.48%
We’re deleveraging while MRVL stands at 3.89%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
10.68%
R&D growth drastically higher vs. MRVL's 1.74%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-1.52%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.